Analyst picks & changes
(GILD)
Analysts covering the Foster City, Calif., company were impressed with data from GILD's Phase II/III study of its
nucleotide analog to treat CMV retinitis in AIDS patients (see BioCentury Extra, Feb. 1). They also noted that the stock had been hit by misconceptions about Vistide's side effects, as well as potential competition from Chiron Corp.'s ganciclovir ocular implant.
Morgan Stanley's Eric Hecht maintained his one-year target
